02047nas a2200397   4500000000100000008004100001260001300042653001500055653001000070653001900080653001600099653002500115653001300140653001100153653001900164653001100183653001400194653001200208653000900220653001600229653001400245653002400259653001700283653001800300100001200318700001700330700001400347700001200361245009800373856005900471300001100530490000700541050001500548520107200563022001401635       2000                            d  c2000 Sep10aAdolescent10aAdult10aCohort Studies10aComorbidity10aConfidence Intervals10aEthiopia10aFemale10aHIV Infections10aHumans10aIncidence10aleprosy10aMale10aMiddle Aged10aPrognosis10aProspective Studies10aRisk Factors10aSurvival Rate1 aGebre S1 aSaunderson P1 aMessele T1 aByass P00aThe effect of HIV status on the clinical picture of leprosy: a prospective study in Ethiopia.  uhttp://leprev.ilsl.br/pdfs/2000/v71n3/pdf/v71n3a14.pdf  a338-430 v71  aGEBRE 20003 a<p>No major interaction between HIV infection and leprosy has been documented. The ALERT MDT Field Evaluation Study (AMFES) has allowed the examination of possible interactions in a prospective manner, although the total number of HIV-positive individuals was not high at 22 (3.8%) of 581 patients tested. There was an excess number of deaths in the HIV-positive group: 27% compared with 5.7% in the HIV-negative group, although the causes of death were not recorded (relative risk 4.8; 95% CI 2.2-10.2). HIV-positive individuals had a higher risk of ENL reactions (relative risk 5.2; 95% CI 1.7-15.9). Reversal reactions and neuritis (both acute and chronic) were not significantly influenced by HIV status, although there was a possible increase in recurrent reversal reactions in HIV-positive cases (relative risk 2.2; 95% CI 0.98-4.7). There was no evidence to suggest an increased risk of developing leprosy or of developing multibacillary rather than paucibacillary disease. There was no association between HIV positivity and the development of impairment.</p>  a0305-7518